

Paroxysmal Non-Kinesigenic Dyskinesias Associated with Biallelic *POLG* Variants: A Case Report

Mutations in mitochondrial DNA polymerase γ (*POLG*) have been described to cause a wide variety of phenotypes.^{1,2} Although less commonly reported, movement disorders have also been described, mainly parkinsonism or complex hyperkinetic movement disorder.^{3,4} We present a child carrying two variants in the *POLG* gene presenting paroxysmal non-kinesigenic dyskinesias (PNKD) as the only manifestation of the disease.

The patient is a 12-year-old girl born to healthy unrelated parents. There was no family history of neurological disease. Early psychomotor development was normal. At the age of 18 months, she began to have paroxysmal dyskinesias, characterized by hyperkinetic complex movements mainly involving the limbs and face, with mixed choreic, dystonic, myoclonic, and ballistic features often resulting in falling to the ground (Video 1).

These episodes, lasting 3 to 5 to 20 minutes, were most commonly observed in the morning after 10 to 20 minutes of wakefulness, but could occur at any time during the day. No precipitating factor was identified. The frequency varied from 1 to 2 times a week to several times a day. Episodes never occurred during sleep.

The patient was first referred to our department at the age of 2.5 years. Neurological examination between episodes was always unremarkable, and cognitive assessment at the last follow-up (age 11 years) was

completely normal (Wechsler Intelligence Scale for Children-IV: Full Scale Score: 100). Extensive metabolic investigations of plasma, urine, and CFS were negative. Brain magnetic resonance imaging (ages 3, 4, 7, 9, and 11 years) was normal. Longitudinal video electroencephalography (EEG) monitoring showed a normal organization of brain activity in both wakefulness and sleep and rare interictal posterior slow abnormalities. Ictal EEG ruled out the epileptic nature of the episodes. Next-generation sequencing analysis of a customized epilepsy/movement disorder gene panel revealed the presence of two variants in the *POLG* (NM_002693.2): a heterozygous missense variant c.3212 G>A; p.Arg1071His (rs774851005) reclassified as likely pathogenic of maternal origin and a novel de novo heterozygous frameshift variant: c.651dupC; p.Ser218LeufsTer26 absent in parents and classified as likely pathogenic. Long-read sequencing and RNAseq confirmed the presence of the two variants in trans (Supporting information Data S1). Whole exome sequencing excluded other genetic causes. Muscle histology and respiratory chain enzyme activity in muscle and fibroblasts were normal. Macrodeletions and multiple deletions of mitochondrial DNA were excluded by Southern



Video 1. Segment 1, age 19 months, during nappy changing, the child presents with an episode of generalized chorea predominantly of the right upper limb, associated with tongue protrusion. Segment 2, age 2.5 years. While standing, the child presents sudden hypertonus of the legs and trunk with a fall to the ground, followed by a choreo-ballistic phase in the left limbs, while the right upper limb remains flexed and adducted. Segment 3, age 4 years. Another episode of generalized hyperkinesia at rest, clearly involving the cranial muscles. Video content can be viewed at <https://onlinelibrary.wiley.com/doi/10.1002/mds.30029>

© 2024 The Author(s). *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Key Words: DNA polymerase gamma (*POLG*), paroxysmal non-kinesigenic dyskinesias (PNKD), next generation sequencing (NGS)

***Correspondence to:** Giovanna Zorzi, Unit of Child Neuropsychiatry-Movement Disorder, Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milan, Italy; E-mail: giovanna.zorzi@istituto-besta.it

Relevant conflicts of interest/financial disclosures: The authors declare that there are no conflicts of interest relevant to this work.

Received: 25 July 2024; **Revised:** 17 September 2024; **Accepted:** 23 September 2024

Published online in Wiley Online Library ([wileyonlinelibrary.com](https://onlinelibrary.wiley.com)). DOI: 10.1002/mds.30029

blotting. Treatments with carbamazepine, clobazam, clonazepam, valproic acid, levetiracetam, acetazolamide, levodopa were all ineffective. Following the identification of variants in *POLG*, at age 9, daily supplementation with riboflavin (300 mg) and coenzyme Q (300 mg) reduced intensity (no longer reported falling to the ground) and frequency (weekly or monthly) of the episodes.

The paroxysmal disorder in our patient can be classified as PNKD according to the following characteristics: lack of association with exercise and movement, prolonged duration, poor response to medication.⁵ Interestingly, the ictal EEG at age 7 (Video S1) showed a persistent slowing triggered by hyperpnea similar to the EEG pattern observed in hemiplegic attacks described in alternating hemiplegia of childhood and hemiplegic migraine and in paroxysmal hemiplegia of GLUT1 deficiency syndrome, suggesting a possible common mechanism.^{6,7} Paroxysmal dyskinesias, mainly exercise induced, are associated with deficiency of a number of mitochondrial enzymes involved in energy production and branched-chain amino acids catabolism: pyruvate dehydrogenase complex, short-chain enoyl-CoA hydratase, 3-hydroxyisobutyryl-CoA hydrolase, succinic semialdehyde dehydrogenase.⁸ Our report broadens the etiological and clinical spectrum to include *POLG*-related condition. ■

Acknowledgments: We acknowledge the Pierfranco and Luisa Mariani Foundation and the Paolo Zorzi Association for Neuroscience ONLUS. Open access funding provided by BIBLIOSAN.

Barbara Castellotti, MSc,¹ Cinzia Gellera, MSc,¹
Davide Caputo, MD,² Federica Rachele Danti, PhD, MD,³
Giuliana Messina, MSc,¹ Marinella Corbetta, MSc,¹
Stefania Magri, PhD,¹ Franco Taroni, MD,¹
Holger Prokisch, PhD,^{4,5} Michael Zech, MD,^{4,5,6} and
Giovanna Zorzi, MD^{1,3*} 

¹Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, ²Unit of Developmental Neurology-Epileptology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, ³Unit of Child Neuropsychiatry-Movement Disorder, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, ⁴Institute of Human Genetics, School of Medicine,

Technical University of Munich, Munich, Germany, ⁵Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany, and ⁶Institute for Advanced Study, Technical University of Munich, Garching, Germany

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

1. Rahman S, Copeland WC. *POLG*-related disorders and their neurological manifestations. *Nat Rev Neurol* 2019;15(1):40–52. <https://doi.org/10.1038/s41582-018-0101-0>
2. Jha R, Patel H, Dubey R, et al. Clinical and molecular spectrum associated with polymerase- γ related disorders. *J Child Neurol* 2022; 37(4):246–255. <https://doi.org/10.1177/08830738211067065>
3. Martikainen MH, Ng YS, Gorman GS, et al. Clinical, genetic, and radiological features of extrapyramidal movement disorders in mitochondrial disease. *JAMA Neurol* 2016;73:668–674.
4. Synofzik M, Schüle R, Schulte C, et al. Complex hyperkinetic movement disorders associated with *POLG* mutations. *Mov Disord* 2010; 25(14):2472–2475. <https://doi.org/10.1002/mds.23307>
5. Gardiner AR, Jaffer F, Dale RC, et al. The clinical and genetic heterogeneity of paroxysmal dyskinesias. *Brain* 2015;138:3567–3580. <https://doi.org/10.1093/brain/awv310>
6. Chastan N, Lebas A, Legoff F, Parain D, Guyant-Marechal L. Clinical and electroencephalographic abnormalities during the full duration of a sporadic hemiplegic migraine attack. *Neurophysiol Clin* 2016;46(4–5):307–311. <https://doi.org/10.1016/j.neucli.2016.03.004>
7. Pellegrin S, Cantalupo G, Opri R, Dalla Bernardina B, Darra F. EEG findings during “paroxysmal hemiplegia” in a patient with GLUT1-deficiency. *Eur J Paediatr Neurol* 2017;21(3):580–582. <https://doi.org/10.1016/j.ejpn.2017.01.002>
8. Garone G, Capuano A, Travaglini L, et al. Clinical and genetic overview of paroxysmal movement disorders and episodic ataxias. *Int J Mol Sci* 2020;21(10):3603. <https://doi.org/10.3390/ijms21103603>

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.

SGML and CITI Use Only DO NOT PRINT

Author Roles

(1) Research Project: A. Conception, B. Organization, C. Execution; (2) Manuscript: A. Writing of the first draft, B. Review and Critique.
G.Z.: 1A, 1B, 1C, 2B
B.C.: 1A, 1B, 1C, 2A
D.C.: 1B, 1C, 2A
S.M.: 1B, 1C
C.G.: 1B, 1C
G.M.: 1C
G.C.: 1C
M.Z.: 1B, 2B
F.R.D.: 1C
F.T.: 2B
H.P.: 2B

Financial Disclosures

Ethical Compliance Statement: The authors confirm that no institutional review board approval was required for this work. The subjects and their legal representatives gave full written consent for genetic analysis for diagnostic and scientific purposes and for video publication. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Funding Sources and Conflicts of Interest: This work was supported by the Italian Ministry of Health (RF-212370491 to B.C.) by EJP RD (EJP RD Joint Transnational Call 2022) and the German Federal Ministry of Education and Research (BMBF, Bonn, Germany), awarded to the project PreDYT (PREdictive biomarkers in DYsTonia, 01GM2302). This research was also supported by a "Schlüsselprojekt" grant from the Else Kröner-Fresenius-Stiftung (2022_EKSE.185). In addition, this study (M.Z.) has received funding from the Federal Ministry of Education and Research (BMBF) and the Free State of Bavaria under the Excellence Strategy of the Federal Government and the Länder, as well as by the Technical University of Munich-Institute for Advanced Study. M.Z. receives research support from the German Research Foundation (DFG 458949627; ZE 1213/2-1). The study was also partially supported by the Italian Ministry of Health (RRC).

Financial Disclosures for the Previous 12 Months: The authors declare that there are no additional disclosures to report.